Synthesis of 2-Aryl-4-aminoquinazolines: Design, Molecular Docking, and In Vitro Assessment of Antibacterial and Cytotoxic Potential.

Fiche publication

Date publication

mars 2026

Journal

International journal of molecular sciences

Auteurs

Membres identifiés du Cancéropôle Est :
Dr VILLA Pascal

Tous les auteurs :
Verdugo F, Braillon C, Mahjoub S, Castro-Alvarez A, Janel-Bintz R, Fechter P, Villa P, Jiménez CA, Donoso-Ruiz DA, Pérez-Fehrmann M, Kesternich V, Ortiz S, Nelson R

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/41898394

Résumé

Antimicrobial resistance (AMR) remains a major threat to modern medicine, fueled by the excessive use of antibiotics and the spread of multidrug-resistant pathogens such as methicillin-resistant (MRSA). In this study, we designed and synthesized a series of 2-aryl-4-aminoquinazoline derivatives bearing an aminoalkylimidazole linker, combining two pharmacophoric motifs associated with antimicrobial activity. Starting from anthranilamide, the compounds were prepared in three straightforward steps, affording good yields and high purity. Their structures were confirmed by FT-IR spectroscopy, H and C nuclear magnetic resonance (NMR), and high-resolution mass spectrometry (HRMS). Biological evaluation showed that series exhibited strong selectivity toward , with compounds and displaying minimum inhibitory concentrations (MICs) between 2.2 and 4.4 µM. No significant activity was observed against other tested strains. Cytotoxicity assays in HepG2 cells revealed moderate to low inhibition. Molecular docking indicated preferential binding to dihydrofolate reductase (DHFR) and relevant interactions with topoisomerase IV, resembling reference inhibitors. ADME analysis predicted favourable absorption, blood-brain barrier permeability, and compliance with Lipinski's rules.